Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study

Autor: Carine Greib, Isabelle Bourdel Marchasson, Fabrice Bonnet, Véronique Cressot, D Breilh, Florent Guerville, Jessica Durrieu, Nicolas Moneger, Julien Ollivier, David Kobeh, Aurélie Lafargue, Rachel Legeron, Albane de Thezy, Claire Roubaud Baudron, Elise Thiel, Geneviève Pinganaud, Carine Foucaud, Marie-Neige Videau, C. Cazanave

Publikováno v: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (12), pp.3546-3554
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (12), pp.3546-3554. ⟨10.1093/jac/dkz385⟩

Background Antibiotic administration by subcutaneous (SC) injection is common practice in French geriatric wards as an alternative to the intravenous (IV) route, but few pharmacokinetic/pharmacodynamic data are available. Ertapenem is useful for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c536df6903b7c763136dd6ced97aa41
https://hal.archives-ouvertes.fr/hal-03162359

Allograft After Pediatric-Inspired Therapy Does Not Improve Young patient's Outcome with High Risk Philadelphia- Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL). A Single Center Report

Autor: Gerald Marit, Carine Foucaud, Marie-Sarah Dilhuydy, Mathieu Sauvezie, Krimo Bouabdallah, Reza Tabrizi, Noel-Jean Milpied, Stephane Vigouroux, Anna Schmitt, Axelle Lascaux, Arnaud Pigneux, Thibaut Leguay

Publikováno v: Blood. 116:3528-3528

Abstract 3528 Allogeneic stem cells transplant (allo-SCT) is currently the preferred therapeutic option for young adults with Ph- ALL in first CR. However, the results of different studies suggested that pediatric-inspired therapy have markedly impro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0712afacdeb5d9a030cdce325df4544
https://doi.org/10.1182/blood.v116.21.3528.3528

Impact of the Use of Thalidomide, Lenalidomide, or Bortezomib, Compared to'standard Chemotherapy', as 'salvage' Before Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC-AT), for Relapsed Multiple Myeloma

Autor: Reza Tabrizi, Krimo Bouabdallah, Gerald Marit, Marie-Sarah Dilhuydy, Carine Foucaud, Thibaut Leguay, Mathieu Sauvezie, Noel-Jean Milpied, Arnaud Pigneux, Jean-Michel Boiron, Anna Schmitt, didier-Innocent Adiko, Stephane Vigouroux

Publikováno v: Blood. 112:4310-4310

In the era of novel drugs, the role of RIC AT for relapsed Multiple Myeloma (MM) remains to be determined. In this retrospective study we analyzed the results of RIC AT performed in 36 patients with relapsed MM in our institution between June 1999 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e03a25f3e052b8aef2b2e93d70ee6e5
https://doi.org/10.1182/blood.v112.11.4310.4310